{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:38:39Z","timestamp":1786649919254,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"\n Aims:<\/jats:title>\n This study was aimed at investigating the prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer (EOC) patients in Lagos, Nigeria.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n This was a retrospective cohort study involving the review of the clinical record of 72 patients with histologically confirmed EOC who were managed at the Lagos University Teaching Hospital, Lagos, Nigeria over a 7-year period from January 2010 to December 2016. Information on the sociodemographic data and platelet counts at diagnosis of EOC were retrieved from the patients' medical records. Descriptive statistics were then computed for all baseline patients' characteristics. Survival analyses were carried out using the Kaplan-Meier estimates. Multivariate analysis of these data was performed with the Cox proportional hazards model.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n This study revealed that the prevalence of pretreatment thrombocytosis was 41.7% among the women with EOC. Fifty-three (73.6%) of the women had the advanced-stage disease (FIGO stage III-IV) while 52 (72.2%) had high-grade disease (II-III). The majority (66.7%) of the women had a serous histological type of EOC while 76.4% had documented recurrence. Pretreatment thrombocytosis was significantly associated with the women's parity (\n P<\/jats:italic>\n = 0.009), serum carbohydrate antigen 125 levels (\n P<\/jats:italic>\n = 0.018), median progression-free survival (PFS) (\n P<\/jats:italic>\n < 0.001), 3-year median overall survival (OS) (\n P<\/jats:italic>\n < 0.001), type of primary treatment (\n P<\/jats:italic>\n = 0.002), extent of cytoreduction (\n P<\/jats:italic>\n < 0.001), presence of ascites (\n P<\/jats:italic>\n = 0.002), International Federation of Gynecology and Obstetrics (FIGO) stage (\n P<\/jats:italic>\n = 0.008), and histological type (\n P<\/jats:italic>\n = 0.011). Pretreatment thrombocytosis was negatively associated with PFS (hazard ratio [HR] = 0.25; 95% CI 0.83, 0.75;\n P<\/jats:italic>\n = 0.014) and 3-year OS (HR = 0.03; 95% CI 0.03, 0.27;\n P<\/jats:italic>\n = 0.002).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n The study suggests that pretreatment thrombocytosis may be a useful predictor of survivals in EOC patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/njcp.njcp_134_19","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T05:53:33Z","timestamp":1597125213000},"page":"1141-1147","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic Impact of Pretreatment Thrombocytosis in Epithelial Ovarian Cancer"],"prefix":"10.4103","volume":"23","author":[{"given":"KS","family":"Okunade","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Lagos, Nigeria"},{"name":"Department of Obstetrics and Gynaecology, Lagos University Teaching Hospital, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Dawodu","sequence":"additional","affiliation":[{"name":"Department of Anatomic and Molecular Pathology, College of Medicine, University of Lagos, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Adenekan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Lagos University Teaching Hospital, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CM","family":"Nwogu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Lagos University Teaching Hospital, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Awofeso","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Lagos University Teaching Hospital, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AO","family":"Ugwu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Lagos University Teaching Hospital, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Salako","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Lagos University Teaching Hospital, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"John-Olabode","sequence":"additional","affiliation":[{"name":"Department of Haematology and Blood Transfusion, College of Medicine, University of Lagos, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"OF","family":"Olowoselu","sequence":"additional","affiliation":[{"name":"Department of Haematology and Blood Transfusion, College of Medicine, University of Lagos, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RI","family":"Anorlu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Lagos, Nigeria"},{"name":"Department of Obstetrics and Gynaecology, Lagos University Teaching Hospital, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"R1-20251006","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20251006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5317\/wjog.v2.i1.1","article-title":"Burden of gynaecological cancers in developing countries","volume":"2","author":"Iyoke","year":"2013","journal-title":"World Obstet Gynaecol"},{"key":"R3-20251006","first-page":"534","article-title":"Pattern of gynaecological cancers in Ghana","volume":"77","author":"Nkyekyer","year":"2000","journal-title":"East Afr Med J"},{"key":"R4-20251006","first-page":"266","article-title":"Pattern of gynaecological cancers in University of Nigeria Teaching Hospital, Enugu, South Eastern Nigeria","volume":"20","author":"Ugwu","year":"2011","journal-title":"Niger J Med"},{"key":"R5-20251006","first-page":"127","article-title":"Ovarian cancers in Ilorin, Nigeria-A review of over 80 cases","volume":"15","author":"Buhari","year":"2005","journal-title":"Nig Q J Hosp Med"},{"key":"R6-20251006","first-page":"114","article-title":"Histopathological patterns of ovarian tumours seen in Lagos University Teaching Hospital: A ten-year retrospective study","volume":"21","author":"Onyiaorah","year":"2011","journal-title":"Nig Q J Hosp Med"},{"key":"R7-20251006","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4103\/1118-4647.187901","article-title":"A five-year review of ovarian cancer at a tertiary institution in Lagos, South-West, Nigeria","volume":"14","author":"Okunade","year":"2016","journal-title":"Niger J Gen Pract"},{"key":"R8-20251006","doi-asserted-by":"crossref","first-page":"8831","DOI":"10.1007\/s13277-015-3533-9","article-title":"Preoperative platelet\/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients","volume":"36","author":"Zhang","year":"2015","journal-title":"Tumour Biol"},{"key":"R9-20251006","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/01443610410001660904","article-title":"Ovarian cancer in Ibadan: Characteristics and management","volume":"24","author":"Odukogbe","year":"2004","journal-title":"J Obstet Gynaecol"},{"key":"R10-20251006","first-page":"143","article-title":"Cancer of the ovary at the University of Benin Teaching Hospital: A 10-year review, 1992-2001","volume":"35","author":"Gharoro","year":"2006","journal-title":"Afr J Med Sci"},{"key":"R11-20251006","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3892\/br.2016.682","article-title":"The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer","volume":"5","author":"Wei","year":"2016","journal-title":"Biomed Rep"},{"key":"R12-20251006","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1021\/pr060344+","article-title":"Elevated levels of phosphorylated fibrinogen-alpha-isoforms and differential expression of other post-translationally modified proteins in the plasma of ovarian cancer patients","volume":"5","author":"Ogata","year":"2006","journal-title":"J Proteome Res"},{"key":"R13-20251006","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1245\/ASO.2003.05.015","article-title":"Cancer antigen 125 associated with multiple benign and malignant pathologies","volume":"10","author":"Miralles","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"R14-20251006","first-page":"695","article-title":"Ovarian endometrioma associated with very high serum CA-125 levels","volume":"26","author":"Shiau","year":"2003","journal-title":"Chang Gung Med J"},{"key":"R15-20251006","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s13224-014-0611-7","article-title":"Evaluation of preoperative serum levels of CA 125 and expression of p53 in ovarian neoplasms: A prospective clinicopathological study in a tertiary care hospital","volume":"66","author":"Tiwari","year":"2016","journal-title":"J Obstet Gynaecol India"},{"key":"R16-20251006","doi-asserted-by":"crossref","first-page":"12079","DOI":"10.1007\/s13277-016-5090-2","article-title":"Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors","volume":"37","author":"Watrowski","year":"2016","journal-title":"Tumour Biol"},{"key":"R17-20251006","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1126\/science.328.5978.562","article-title":"Cell biology: Beyond clotting: The powers of platelets","volume":"328","author":"Leslie","year":"2010","journal-title":"Science"},{"key":"R18-20251006","first-page":"237","article-title":"Zur pathologischen anatomie des blutes","volume":"39","author":"Riess","year":"1872","journal-title":"Arch Anat Physiol Wissensch Med"},{"key":"R19-20251006","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/archinte.1964.03860100079008","article-title":"Thrombocytosis associated with malignant disease","volume":"114","author":"Levin","year":"1964","journal-title":"Arch Intern Med"},{"key":"R20-20251006","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1586\/14737140.8.8.1247","article-title":"The role of platelet activation in tumor metastasis","volume":"8","author":"Borsig","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"R21-20251006","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.3802\/jgo.2019.30.e5","article-title":"Association of pretreatment thrombocytosis with prognosis in ovarian cancer: A systematic review and meta-analysis","volume":"30","author":"Ye","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"R22-20251006","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1110352","article-title":"Paraneoplastic thrombocytosis in ovarian cancer","volume":"366","author":"Stone","year":"2012","journal-title":"N Engl J Med"},{"key":"R23-20251006","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ygyno.2013.05.038","article-title":"Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer","volume":"130","author":"Allensworth","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R24-20251006","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ajcp\/88.1.106","article-title":"Platelet counts in three racial groups","volume":"88","author":"Saxena","year":"1987","journal-title":"Am J Clin Pathol"},{"key":"R25-20251006","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12885-016-2070-2","article-title":"Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients","volume":"16","author":"Feng","year":"2016","journal-title":"BMC Cancer"},{"key":"R26-20251006","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/jog.12151","article-title":"Prognostic significance of thrombocytosis, platelet parameters and aggregation rates in epithelial ovarian cancer","volume":"40","author":"Ma","year":"2014","journal-title":"J Obstet Gynaecol Res"},{"key":"R27-20251006","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1447-0756.2011.01780.x","article-title":"Preoperative plasma fibrinogen, platelet count and prognosis in epithelial ovarian cancer","volume":"38","author":"Qiu","year":"2012","journal-title":"J Obstet Gynaecol Res"},{"key":"R28-20251006","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1634\/theoncologist.2009-0079","article-title":"Plasma fibrinogen levels and prognosis in patients with ovarian cancer: A multicenter study","volume":"14","author":"Polterauer","year":"2009","journal-title":"Oncologist"},{"key":"R29-20251006","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/IGC.0000000000000303","article-title":"Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism","volume":"25","author":"Man","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"R30-20251006","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejim.2013.01.017","article-title":"The platelet-cancer loop","volume":"24","author":"Goubran","year":"2013","journal-title":"Eur J Intern Med"},{"key":"R31-20251006","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3004","article-title":"Contribution of platelets to tumour metastasis","volume":"11","author":"Gay","year":"2011","journal-title":"Nat Rev Cancer"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_134_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:53Z","timestamp":1786647593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_134_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_134_19","relation":{},"ISSN":["1119-3077","2229-7731"],"issn-type":[{"value":"1119-3077","type":"print"},{"value":"2229-7731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"2019-03-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}